The effects of recombinant human erythropoietin (rHuEPO) administration on blood pressure and urinary albumin excretion were studied in normotensive Wistar-Kyoto rats (WKY), in spontaneously hypertensive rats (SHR), and in SHR rats treated with an angiotensin converting enzyme inhibitor (SHR-ACEi). Rats were housed in metabolic cages and treated with rHuEPO (150 U/kg body weight [bw] three times a week) for 6 weeks, Control animals received the vehicle only (0.25 mL of physiological saline). An angiotensin converting enzyme inhibitor was administered in the drinking water for 6 weeks (spirapril 5 mg/kg bw). Systolic blood pressure (SEP), and 24 h urinary albumin excretion (UAE) were measured once a week. No significant differences in SEP were observed between rHuEPO and vehicle treated normotensive animals at the end of the treatment (171.9 ± 4.9 v 172.1 ± 5.6 mm Hg, respectively). After 6 weeks, SEP was significantly higher in SHR and SHR-ACEi groups treated with rHuEPO than in control groups (239.8 ± 7.3 and 243.0 ± 7.4 mm Hg v 218.1 ± 6.0 and 187.9 ± 4.6 mm Hg, respectively); UAE was significantly higher in groups treated with rHuEPO than in control groups (WKY: 265.9 ± 19.5 v 127.0 ± 12.3 μg/100 g bw, SHR: 1668.4 ± 564.6 v 234.8 ± 22.9 μg/100 g bw, and SHR-ACEi: 1522.7 ± 448.3 v 143.0 ± 18.9 μg/100 g bw, respectively). We concluded that erythropoietin treatment causes an increase in arterial pressure in ShR only, and an increase in UAE in both normotensive and hypertensive rats. The albuminuric effect was not entirely dependent on increased blood pressure. The treatment with an angiotensin converting enzyme inhibitor did not modify either the proteinuric or the pressor effects.
- Angiotensin converting enzyme inhibitors
- Blood pressure
- Spontaneously hypertensive rat
- Wista-Kyoto rat
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine